Improved pharmacokinetics of tenofovir ester prodrugs strengthened the inhibition of HBV replication and the rebalance of hepatocellular metabolism in preclinical models
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Improved pharmacokinetics of tenofovir ester prodrugs strengthened the inhibition of HBV replication and the rebalance of hepatocellular metabolism in preclinical models
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-08-29
DOI
10.3389/fphar.2022.932934
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Can we cure hepatitis B virus with novel direct‐acting antivirals?
- (2020) Maria G. Martinez et al. LIVER INTERNATIONAL
- Multi-omics profiling reveals protective function of Schisandra lignans against acetaminophen-induced hepatotoxicity
- (2020) Caixia Yan et al. DRUG METABOLISM AND DISPOSITION
- Design, Synthesis, and Anti-HBV Activity of New Bis(l-amino acid) Ester Tenofovir Prodrugs
- (2019) Apeng Wang et al. ACS Medicinal Chemistry Letters
- Rat intestinal drug permeability: A status report and summary of repeated determinations
- (2019) I.R. Dubbelboer et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- Octadecyloxyethyl benzyl tenofovir: A novel tenofovir diester provides sustained intracellular levels of tenofovir diphosphate
- (2019) James R. Beadle et al. ANTIVIRAL RESEARCH
- Review article: clinical pharmacology of current and investigational hepatitis B virus therapies
- (2019) Elise J. Smolders et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Tenofovir Versus Entecavir for the Treatment of Acute-on-Chronic Liver Failure due to Reactivation of Chronic Hepatitis B With Genotypes B and C
- (2018) Yue-Meng Wan et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Absorption sites of orally administered drugs in the small intestine
- (2017) Teruo Murakami Expert Opinion on Drug Discovery
- Simultaneous determination of tenofovir alafenamide and its active metabolites tenofovir and tenofovir diphosphate in HBV-infected hepatocyte with a sensitive LC–MS/MS method
- (2017) Bingchen Ouyang et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus
- (2016) Adrian S. Ray et al. ANTIVIRAL RESEARCH
- Bioanalytical assay development and validation for simultaneous quantification of five schisandra lignans in rat primary hepatocytes based on LC-MS/MS: application to a real-time uptake study for Schisandra Lignan Extract
- (2016) Dian Kang et al. BIOMEDICAL CHROMATOGRAPHY
- Mechanisms of HBV-induced hepatocellular carcinoma
- (2016) Massimo Levrero et al. JOURNAL OF HEPATOLOGY
- HIV infection and bone disease
- (2016) J. Compston JOURNAL OF INTERNAL MEDICINE
- Reduction Sensitive Lipid Conjugates of Tenofovir: Synthesis, Stability, and Antiviral Activity
- (2016) Kyle E. Giesler et al. JOURNAL OF MEDICINAL CHEMISTRY
- Stability behaviour of antiretroviral drugs and their combinations. 4: Characterization of degradation products of tenofovir alafenamide fumarate and comparison of its degradation and stability behaviour with tenofovir disoproxil fumarate
- (2016) Vijaya Madhyanapu Golla et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- Pharmacokinetics in Vitro and in Vivo of Two Novel Prodrugs of Oleanolic Acid in Rats and Its Hepatoprotective Effects against Liver Injury Induced by CCl4
- (2016) Zongjiang Yu et al. MOLECULAR PHARMACEUTICS
- Metabolic characterization of the natural progression of chronic hepatitis B
- (2016) Johannes C. Schoeman et al. Genome Medicine
- Implications of Efficient Hepatic Delivery by Tenofovir Alafenamide (GS-7340) for Hepatitis B Virus Therapy
- (2015) Eisuke Murakami et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroVirology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate
- (2015) Christian Callebaut et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection
- (2015) Kosh Agarwal et al. JOURNAL OF HEPATOLOGY
- Anti-HBV Drugs: Progress, Unmet Needs, and New Hope
- (2015) Lei Kang et al. Viruses-Basel
- Synthesis of Nucleoside Phosphate and Phosphonate Prodrugs
- (2014) Ugo Pradere et al. CHEMICAL REVIEWS
- Tenofovir Alafenamide Vs. Tenofovir Disoproxil Fumarate in Single Tablet Regimens for Initial HIV-1 Therapy
- (2014) Paul E. Sax et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults
- (2014) M. Markowitz et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Role of HBV Replication in Host Cell Metabolism: A Proteomics Analysis
- (2013) Laleh Sadrolodabaee et al. Current Proteomics
- Antiviral Activity, Safety, and Pharmacokinetics/Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1–Positive Adults
- (2013) Peter J. Ruane et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Phase Diagrams Map the Properties of Antiviral Agents Directed against Hepatitis B Virus Core Assembly
- (2012) Lichun Li et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antiviral therapies: Focus on hepatitis B reverse transcriptase
- (2012) Eleftherios Michailidis et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Mechanism for Effective Lymphoid Cell and Tissue Loading Following Oral Administration of Nucleotide Prodrug GS-7340
- (2012) Darius Babusis et al. MOLECULAR PHARMACEUTICS
- Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B
- (2011) J. Fung et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202
- (2011) Grace A. McComsey et al. JOURNAL OF INFECTIOUS DISEASES
- Systematic Review and Meta‐analysis: Renal Safety of Tenofovir Disoproxil Fumarate in HIV‐Infected Patients
- (2010) Ryan D. Cooper et al. CLINICAL INFECTIOUS DISEASES
- Prodrug Design to Improve Pharmacokinetic and Drug Delivery Properties: Challenges to the Discovery Scientists
- (2010) S. Jana et al. CURRENT MEDICINAL CHEMISTRY
- 20(S)-Ginsenoside Rh2 Noncompetitively Inhibits P-Glycoprotein In Vitro and In Vivo: A Case for Herb-Drug Interactions
- (2010) J. Zhang et al. DRUG METABOLISM AND DISPOSITION
- Nucleotide Analogue Prodrug Tenofovir Disoproxil Enhances Lymphoid Cell Loading following Oral Administration in Monkeys
- (2009) Lucie Durand-Gasselin et al. MOLECULAR PHARMACEUTICS
- Unknown
- (2008) G. Birkus et al. MOLECULAR PHARMACOLOGY
- Hepatocytes proteomic alteration and seroproteome analysis of HBV-transgenic mice
- (2008) Chen Ding et al. PROTEOMICS
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started